The epidemic of oesophageal carcinoma: Where are we now?

Cancer Epidemiology

Volumn 41, Issue , 2016, Pages 88-95

  Thrift, Aaron P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Barrett's oesophagus; Epidemiology; Gastro oesophageal reflux disease; Obesity; Oesophageal cancer

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL OBESITY; ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DEMOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING; ADENOCARCINOMA; COMPLICATION; ESOPHAGUS TUMOR; INCIDENCE; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; OBESITY; RISK FACTORS; SMOKING;

EID: 84960855424     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.01.013     Document Type: Review

References (61)

1. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. (2014). Available from: , accessed on 16/01/2015. http://globocan.iarc.fr.
2. Arnold M., Pandeya N., Byrnes G., Renehan A.G., Stevens G.A., Ezzati M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015, 16:36-46.
3. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 2005, 97:142-146.
4. Thrift A.P., Whiteman D.C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann. Oncol. 2012, 23:3155-3162.
5. Edgren G., Adami H.O., Weiderpass E., Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013, 62:1406-1414.
6. Engel L.S., Chow W.H., Vaughan T.L., Gammon M.D., Risch H.A., Stanford J.L., et al. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 2003, 95:1404-1413.
7. Olsen C.M., Pandeya N., Green A.C., Webb P.M., Whiteman D.C. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am. J. Epidemiol. 2011, 174:582-590.
8. Ronkainen J., Aro P., Storskrubb T., Johansson S.E., Lind T., Bolling-Sternevald E., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
9. Hvid-Jensen F., Pedersen L., Drewes A.M., Sorensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 2011, 365:1375-1383.
10. Desai T.K., Krishnan K., Samala N., Singh J., Cluley J., Perla S., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
11. Corley D.A., Mehtani K., Quesenberry C., Zhao W., de Boer J., Weiss N.S. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013, 145:312-319.
12. Bhat S.K., McManus D.T., Coleman H.G., Johnston B.T., Cardwell C.R., McMenamin U., et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 2015, 64:20-25.
13. Whiteman D.C. Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma. Gut 2015, 64:5-6.
14. Verbeek R.E., Leenders M., Ten Kate F.J., van Hillegersberg R., Vleggaar F.P., van Baal J.W., et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am. J. Gastroenterol. 2014, 109:1215-1222.
15. El-Serag H.B., Naik A.D., Duan Z., Shakhatreh M., Helm A., Pathak A., et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut 2015, [Epub ahead of print].
16. Pohl H., Pech O., Arash H., Stolte M., Manner H., May A., et al. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 2016, 65:196-201.
17. Kastelein F., van Olphen S.H., Steyerberg E.W., Spaander M.C., Bruno M.J. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression. Gut 2016, 65:196-201.
18. Pandeya N., Olsen C.M., Whiteman D.C. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol. 2013, 37:579-584.
19. Taylor P.R., Abnet C.C., Dawsey S.M. Squamous dysplasia-the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2013, 22:540-552.
20. Howlader N., Noone A.M., Krapcho M., Garshell J., Miller D., Altekruse S.F., Kosary C.L., Yu M Ruhl J, Tatalovich Z., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A. SEER Cancer Statistics Review, 1975-2011 2013, National Cancer Institute, Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975_2011/.
21. Surveillance Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. http://www.seer.cancer.gov.
22. Nordenstedt H., El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006). Scand. J. Gastroenterol. 2011, 46:597-602.
23. Cook M.B., Chow W.H., Devesa S.S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br. J. Cancer 2009, 101:855-859.
24. Thrift A.P., El-Serag H.B. Sex and racial disparity in incidence of esophageal adenocarcinoma: observations and explanations. Clin. Gastroenterol. Hepatol. 2015, [Epub ahead of print].
25. Lagergren J., Bergstrom R., Lindgren A., Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999, 340:825-831.
26. Cook M.B., Corley D.A., Murray L.J., Liao L.M., Kamangar F., Ye W., et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One 2014, 9:e103508.
27. Thrift A.P., Kramer J.R., Qureshi Z., Richardson P.A., El-Serag H.B. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am. J. Gastroenterol. 2013, 108:915-922.
28. Yoshida N. Inflammation and oxidative stress in gastroesophageal reflux disease. J. Clin. Biochem. Nutr. 2007, 40:13-23.
29. Cook M.B., Kamangar F., Whiteman D.C., Freedman N.D., Gammon M.D., Bernstein L., et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J. Natl. Cancer Inst. 2010, 102:1344-1353.
30. Pandeya N., Williams G.M., Sadhegi S., Green A.C., Webb P.M., Whiteman D.C. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. Am. J. Epidemiol. 2008, 168:105-114.
31. Pandeya N., Williams G., Green A.C., Webb P.M., Whiteman D.C. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009, 136:1215-1224.
32. Prabhu A., Obi K.O., Rubenstein J.H. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am. J. Gastroenterol. 2014, 109:822-827.
33. Singh S., Sharma A.N., Murad M.H., Buttar N.S., El-Serag H.B., Katzka D.A., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013, 11:1399-1412.
34. Hazelton W.D., Curtius K., Inadomi J.M., Vaughan T.L., Meza R., Rubenstein J.H., et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 2015, 24:1012-1023.
35. Kong C.Y., Nattinger K.J., Hayeck T.J., Omer Z.B., Wang Y.C., Spechler S.J., et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol. Biomarkers Prev. 2011, 20:2450-2456.
36. Kroep S., Lansdorp-Vogelaar I., Rubenstein J.H., Lemmens V.E., van Heijningen E.B., Aragones N., et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am. J. Gastroenterol. 2014, 109:336-343.
37. Adams R.J., Appleton S., Wilson D.H., Taylor A.W., Dal Grande E., Chittleborough C., et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005, 28:2777-2779.
38. Yang X., Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer. Diabetologia 2007, 50:1127-1139.
39. Hoyo C., Cook M.B., Kamangar F., Freedman N.D., Whiteman D.C., Bernstein L., et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int. J. Epidemiol. 2012, 41:1706-1718.
40. Steffen A., Huerta J.M., Weiderpass E., Bueno-de-Mesquita H.B., May A.M., Siersema P.D., et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2015, 137:646-657.
41. Lindkvist B., Johansen D., Stocks T., Concin H., Bjorge T., Almquist M., et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer 2014, 14:103.
42. Yang L., Colditz G.A. Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern. Med. 2015, 175:1412-1413.
43. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig. Dis. Sci. 2008, 53:2307-2312.
44. Thrift A.P., Shaheen N.J., Gammon M.D., Bernstein L., Reid B.J., Onstad L., et al. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J. Natl. Cancer Inst. 2014, 106:dju252.
45. Cook M.B., Freedman N.D., Gamborg M., Sorensen T.I., Baker J.L. Childhood body mass index in relation to future risk of oesophageal adenocarcinoma. Br. J. Cancer 2015, 112:601-607.
46. Levi Z., Kark J.D., Shamiss A., Derazne E., Tzur D., Keinan-Boker L., et al. Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer 2013, 119:4086-4093.
47. Vaughan T.L., Davis S., Kristal A., Thomas D.B. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 1995, 4:85-92.
48. Lahmann P.H., Pandeya N., Webb P.M., Green A.C., Whiteman D.C. Body mass index, long-term weight change, and esophageal squamous cell carcinoma: is the inverse association modified by smoking status. Cancer 2012, 118:1901-1909.
49. Freedman N.D., Murray L.J., Kamangar F., Abnet C.C., Cook M.B., Nyren O., et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011, 60:1029-1037.
50. Liao L.M., Vaughan T.L., Corley D.A., Cook M.B., Casson A.G., Kamangar F., et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012, 142:442-452.
51. Sadeghi S., Bain C.J., Pandeya N., Webb P.M., Green A.C., Whiteman D.C. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1169-1178.
52. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998, 7:97-102.
53. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991, 325:1127-1131.
54. Nie S., Chen T., Yang X., Huai P., Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis. Esophagus 2014, 27:645-653.
55. Xie F.J., Zhang Y.P., Zheng Q.Q., Jin H.C., Wang F.L., Chen M., et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J. Gastroenterol. 2013, 19:6098-6107.
56. Nguyen T.H., Thrift A.P., Ramsey D., Green L., Shaib Y.H., Graham D.Y., et al. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am. J. Gastroenterol. 2014, 109:1870-1880.
57. Thrift A.P., Kendall B.J., Pandeya N., Whiteman D.C. A model to determine absolute risk for esophageal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2013, 11:138-144.
58. Thrift A.P., Kendall B.J., Pandeya N., Vaughan T.L., Whiteman D.C. A clinical risk prediction model for Barrett esophagus. Cancer Prev. Res. (Phila) 2012, 5:1115-1123.
59. Rubenstein J.H., Morgenstern H., Appelman H., Scheiman J., Schoenfeld P., McMahon L.F., et al. Prediction of Barrett's esophagus among men. Am. J. Gastroenterol. 2013, 108:353-362.
60. Thrift A.P., Garcia J.M., El-Serag H.B. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2014, 12:1267-1271.
61. Rubenstein J.H., Thrift A.P. Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus. Best Pract. Res. Clin. Gastroenterol. 2015, 29:41-50.